BridgeMD
CK-0045 proof-of-concept study
EU CTIS ID: 2024-514191-41-00
What this study is testing
To investigate the effects of 16 weeks of treatment with CK-0045 at two different dose levels versus placebo on glucose metabolism after a mixed meal tolerance test (MMTT) in participants with overweight / obesity and Type 2 diabetes.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male or female person diagnosed with type 2 diabetes mellitus.
- Age between 18 and 74 years, both inclusive, at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus ≥ 6 months prior to screening.
- Treated with diet and exercise and a maximum of three antidiabetic medications at stable doses for at least 3 months prior to screening.
- Body Mass Index (BMI) between 27.0 and 40.0 kg/m^2 and HbA1c 6.5-8.5 for participants taking 3 antidiabetic medications or HbA1c 6.5-9.0% for participants taking 2 or less antidiabetic medications at screening
You likely can't join if
- Any of the following within the past 6 months prior to screening: myocardial infarction, unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack, cerebrovascular accident or decompensated congestive heart failure, or currently have New York Health Association Class III or IV heart failure or any other clinically significant history or evidence of poorly controlled cardiovascular disorder(s) as judged by the investigator.
- Have a known clinically significant gastric emptying abnormality (for example, severe diabetic gastroparesis or gastric outlet obstruction), have undergone gastric bypass (bariatric) surgery or restrictive bariatric surgery (for example, gastric banding ), and/or device-based therapy for obesity, or have had device removal within the past 6 months.
- History or signs of clinically relevant skin diseases including but not limited to: psoriasis, atopic dermatitis, eczema, etc., as judged by the investigator.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.